Retatrutide + MOTS-c + Tesamorelin

The combination is built on three non-redundant arms:

1. Retatrutide handles the broad fat-loss arm via triple incretin agonism (appetite, glycemic control, energy expenditure).
2. MOTS-c handles the mitochondrial / metabolic-flexibility arm — the hypothesis is that supporting skeletal muscle's metabolic infrastructure during the caloric deficit prevents the metabolic adaptation that often accompanies sustained weight loss.
3. Tesamorelin handles the visceral-fat-specific arm — its FDA labeling for HIV lipodystrophy reflects an unusually clean visceral-adipose-tissue-reducing effect, distinct from generalized GH replacement.

The three-arm logic is why this combination has caught attention: it is structurally non-overlapping in mechanism, addressing fat loss, metabolic adaptation, and adipose-distribution all separately. Whether those mechanisms compound additively or in some lesser combined fashion in actual humans is the empirical question — and one that has not been answered.

The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.

• Does the three-arm combination produce body-composition outcomes meaningfully better than retatrutide + standard care alone?
• Is MOTS-c administered exogenously a viable strategy for the metabolic-flexibility goal it's invoked for?
• What are the cumulative cardiovascular implications (heart rate, arrhythmia risk) of triple incretin + GHRH co-administration?

The Retatrutide + MOTS-c + Tesamorelin stack is the most discussed next-generation "recomposition" combination in current biohacker and clinical-anti-aging discourse. The mechanistic story is unusually coherent for a community-derived stack — three non-overlapping arms with credible logic for each. The fundamental honest framing remains that this is a theoretical combination of one investigational drug, one approved drug used outside its labeled indication, and one investigational mitochondrial peptide. Combination-specific human evidence is absent; per-compound evidence is at very different levels. For anyone tracking this stack, the appropriate stance is intellectual interest in the design, paired with explicit recognition that what we have is mechanistic argument plus small-N reports — not controlled trials.